Researchers Identify Heterogeneity of Tissue Resident Memory T Cells as Targets of Checkpoint Therapies
Yale Cancer Center/Smilow Cancer HospitalResearchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.